Matches in Nanopublications for { ?s ?p "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1231166.RAdQJpyP2rP2oU4lm9xvD-FqKprDIoMxbUnt_zcMTxBSE130_assertion description "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231166.RAdQJpyP2rP2oU4lm9xvD-FqKprDIoMxbUnt_zcMTxBSE130_provenance.
- NP1231167.RAXo8O6HK4rUrV4AG_92sITbhUz7Axr1POf5q_EjZrzwo130_assertion description "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231167.RAXo8O6HK4rUrV4AG_92sITbhUz7Axr1POf5q_EjZrzwo130_provenance.
- NP1231168.RAQM4lULCBZs74eS4PbXcgfmPXFs0SujdeM1kfxdYpnoA130_assertion description "[In addition, loss of Smad4 staining was more likely to be found in older (OR?=?1.69, 95% CI: 1.09-2.61; Pheterogeneity?=?0.648) colorectal cancer patients with a late tumor stage (OR?=?2.31, 95% CI: 1.71-3.10; Pheterogeneity?=?0.218) and in gastric cancer patients with lymph node metastasis (OR?=?2.11, 95% CI: 1.03-4.34; Pheterogeneity?=?0.038).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231168.RAQM4lULCBZs74eS4PbXcgfmPXFs0SujdeM1kfxdYpnoA130_provenance.